A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies
NCT00772876
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
P1446A-05
Sponsor
Piramal Enterprises Limited